Add to ORKGThis work was supported by Portuguese Foundation for Science and Technology, Center for Studies in Education, Technologies and by Health and by strategic project PEst-OE/CED/UI4016/201
Background. In this study we tested the hypothesis that sirolimus (a target of rapamycin inhibitor t...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use ...
Sirolimus (SRL) have been pointed as a feasible option for minimize the use of cyclosporine A (CsA),...
Side-effect minimization strategies to avoid serious side-effects of cyclosporine A (CsA), such as n...
End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms under...
Copyright © 2014 Jose ́ Sereno et al. This is an open access article distributed under the Creative ...
Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunot...
Cyclosporin (CsA) has been progressively replaced by other drugs with putatively fever side effects,...
Protocols of conversion from cyclosporine A (CsA) to sirolimus (SRL) have been widely used in immuno...
Calcineurin inhibitors exacerbate ischemic injury in transplanted kidneys, but it is not known if si...
Sirolimus, a macrocylic lactone, blocks T-cell activation by a mechanism of action distinct from cal...
Background: Ischemia-reperfusion (I/R) is present at various degrees in kidney transplants. I/R play...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine ne...
Background. In this study we tested the hypothesis that sirolimus (a target of rapamycin inhibitor t...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use ...
Sirolimus (SRL) have been pointed as a feasible option for minimize the use of cyclosporine A (CsA),...
Side-effect minimization strategies to avoid serious side-effects of cyclosporine A (CsA), such as n...
End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms under...
Copyright © 2014 Jose ́ Sereno et al. This is an open access article distributed under the Creative ...
Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunot...
Cyclosporin (CsA) has been progressively replaced by other drugs with putatively fever side effects,...
Protocols of conversion from cyclosporine A (CsA) to sirolimus (SRL) have been widely used in immuno...
Calcineurin inhibitors exacerbate ischemic injury in transplanted kidneys, but it is not known if si...
Sirolimus, a macrocylic lactone, blocks T-cell activation by a mechanism of action distinct from cal...
Background: Ischemia-reperfusion (I/R) is present at various degrees in kidney transplants. I/R play...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine ne...
Background. In this study we tested the hypothesis that sirolimus (a target of rapamycin inhibitor t...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use ...